Table 3 FDA-approved therapeutic drugs for gynecologic cancers
Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
Paclitaxel (Taxol) | HQ Spclt | Microtubule-stabilizing agent | Advanced ovarian cancer | 12/29/1992 | P, O |
Olaparib (Lynparza) | AstraZeneca | PARP inhibitor | Advanced BRCA-mutated ovarian cancer | 12/19/2014 | P, O |
Rucaparib camsylate (Rubraca) | Clovis Oncology | PARP inhibitor | BRCA-positive ovarian cancer | 12/19/2016 | P, O |
Niraparib tosylate (Zejula) | GlaxoSmithKline | PARP inhibitor | Epithelial ovarian, fallopian tube, or primary peritoneal cancer | 03/27/2017 | P, O |
Dostarlimab (Jemperli) | GlaxoSmithKline | PD1-directed mAb | Endometrial cancer | 04/22/2021 | P |
Tisotumab vedotin (Tivdak) | Seagen | TF-targeted ADC | Cervical cancer | 09/20/2021 | P, O |